IL-25 enhances allergic airway inflammation by amplifying a TH2 cell–dependent pathway in mice
…, K Ikeda, S Kagami, M Hatano, Y Seto… - Journal of allergy and …, 2006 - Elsevier
BACKGROUND: A novel IL-17 family cytokine, IL-25, has been reported to induce IL-4, IL-5,
and IL-13 production from undefined non-T/non-B cells and then induce T H 2-type immune …
and IL-13 production from undefined non-T/non-B cells and then induce T H 2-type immune …
Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line Cε transcription of IL-4–stimulated B cells
…, K Hirose, K Suzuki, S Kagami, Y Seto… - Blood, The Journal …, 2002 - ashpublications.org
Interleukin 21 (IL-21) has recently been identified as a multifunctional cytokine that induces
the proliferation of T cells and B cells and differentiation of natural killer cells. To determine …
the proliferation of T cells and B cells and differentiation of natural killer cells. To determine …
Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of …
…, M Kohno, S Hirata, M Kishimoto, Y Seto… - Modern …, 2023 - academic.oup.com
Objective The aim of this study was to update the Japan College of Rheumatology (JCR)
clinical practice guidelines (CPG) for the management of rheumatoid arthritis (RA; JCR CPG for …
clinical practice guidelines (CPG) for the management of rheumatoid arthritis (RA; JCR CPG for …
C‐reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to …
MH Buch, Y Seto, SJ Bingham… - … : Official Journal of …, 2005 - Wiley Online Library
Objective Nonresponse to anti–tumor necrosis factor α in patients with rheumatoid arthritis (RA)
is poorly understood. The aims of this study were to define nonresponse patterns using …
is poorly understood. The aims of this study were to define nonresponse patterns using …
Management of rheumatoid arthritis: the 2012 perspective
H Yamanaka, Y Seto, E Tanaka, T Furuya… - Modern …, 2013 - Taylor & Francis
Management of rheumatoid arthritis (RA) has improved over the last 10 years. These
changes have been monitored in the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) …
changes have been monitored in the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) …
Enhanced Th2 cell-mediated allergic inflammation in Tyk2-deficient mice
Allergic inflammation is mediated by Th2 cell-derived cytokines, including IL-4, IL-5, and IL-13,
and down-regulated by IFN-γ and IL-12. Tyk2 is a member of the Janus family of protein …
and down-regulated by IFN-γ and IL-12. Tyk2 is a member of the Janus family of protein …
Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis
…, A Kobayashi, K Shidara, N Sugimoto, Y Seto… - Clinical …, 2015 - Springer
To clarify the impact of comorbidities on treatment strategies and outcomes in patients with
rheumatoid arthritis (RA) using a large observational RA cohort, the presence of …
rheumatoid arthritis (RA) using a large observational RA cohort, the presence of …
Postoperative complications in patients with rheumatoid arthritis using a biological agent–a systematic review and meta-analysis
…, Y Kawahito, M Kishimoto, Y Seto… - Modern …, 2015 - academic.oup.com
Objectives. To evaluate, through a systematic review of the literature, the association between
the use of biological disease-modifying antirheumatic drugs (bDMARDs) and surgical site …
the use of biological disease-modifying antirheumatic drugs (bDMARDs) and surgical site …
Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical …
…, M Kishimoto, Y Kaneko, H Tamai, Y Seto… - Modern …, 2022 - academic.oup.com
Objectives To evaluate the efficacy and safety of biosimilars compared with reference biological
disease modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (…
disease modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (…
Does exercise therapy improve patient-reported outcomes in rheumatoid arthritis? A systematic review and meta-analysis for the update of the 2020 JCR guidelines …
…, M Kishimoto, M Kohno, T Sugihara, Y Seto… - Modern …, 2022 - academic.oup.com
Objectives This study aimed to evaluate the impact of exercise therapy on patient-reported
outcomes (PROs) in rheumatoid arthritis (RA) as part of the process of updating the 2020 …
outcomes (PROs) in rheumatoid arthritis (RA) as part of the process of updating the 2020 …